668 related articles for article (PubMed ID: 19029980)
1. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
2. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
Leiva M; Moretti S; Soilihi H; Pallavicini I; Peres L; Mercurio C; Dal Zuffo R; Minucci S; de Thé H
Leukemia; 2012 Jul; 26(7):1630-7. PubMed ID: 22333881
[TBL] [Abstract][Full Text] [Related]
4. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
5. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
6. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Zhu J; Lallemand-Breitenbach V; de Thé H
Oncogene; 2001 Oct; 20(49):7257-65. PubMed ID: 11704854
[TBL] [Abstract][Full Text] [Related]
7. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
8. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
[TBL] [Abstract][Full Text] [Related]
10. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
11. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Dos Santos GA; Kats L; Pandolfi PP
J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
Barbarroja N; Siendones E; Torres LA; Luque MJ; Martinez JM; Dorado G; Velasco F; Torres A; López-Pedrera C
Br J Haematol; 2008 Jul; 142(1):27-35. PubMed ID: 18445086
[TBL] [Abstract][Full Text] [Related]
13. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
14. Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.
Mozziconacci MJ; Rosenauer A; Restouin A; Fanelli M; Shao W; Fernandez F; Toiron Y; Viscardi J; Gambacorti-Passerini C; Miller WH; Lafage-Pochitaloff M
Genes Chromosomes Cancer; 2002 Nov; 35(3):261-70. PubMed ID: 12353268
[TBL] [Abstract][Full Text] [Related]
15. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.
Duprez E; Wagner K; Koch H; Tenen DG
EMBO J; 2003 Nov; 22(21):5806-16. PubMed ID: 14592978
[TBL] [Abstract][Full Text] [Related]
16. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
Kamashev D; Vitoux D; De Thé H
J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
[TBL] [Abstract][Full Text] [Related]
17. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
18. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
19. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
